Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Plinabulin (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Nereus Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2018 Data from overall CIN development program and safety data from NSCLC Study 101 and Study 103, will support a new drug application submission for CIN to the China Food and Drug Administration (CFDA) in late 2018 or early 2019.
    • 21 Feb 2017 Results published in the BeyondSpring Pharmaceuticals Media Release
    • 21 Feb 2017 According to a BeyondSpring Pharmaceuticals media release, data from this trial has been selected for presentation at ASCO-SITC Clinical Immuno-Oncology Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top